疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋

疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋
疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋

The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program

PD-L1 is a proven biomarker for patient response to KEYTRUDA®疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋 (pembrolizumab) in NSCLC (PD-L1 IHC 22C3 pharmDx [package insert], 2019). Review how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Tumor Proportion Score (TPS)疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋.

The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:

疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋
  • Understand the core principles of PD-L1 pathology
  • Learn the process for evaluating stained specimens for PD-L1 expression
  • Recognize confounding considerations that affect PD-L1 interpretation
  • Score images for PD-L1 expression across a variety of patient samples
疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋Review the PD-L1 IHC 22C3 pharmDx Intended Use
For countries outside of the United States, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.
疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋

Get started

REGISTER NOW 疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋
Already registered? LOGIN NOW
疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋
疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋 疯狂的撞击她的娇嫩H.翁公的粗大炮.好剧屋